[1] |
LIU Ting, CAO Zhongqiang, HE Wenjia, YUAN Xiuli, CHEN Zebin, LI Xuejuan.
One case of acute severe pancreatitis caused by pegaspargase and its etiology
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1075-1077.
|
[2] |
WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru.
Foreign methods for benefit-risk assessment of pharmaceutical products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.
|
[3] |
WANG Yuxi, ZHANG Zonglin, WANG Yingli, CHEN Yafei, LI Junsheng, HUO Yanfei, XIE Yanjun, LIU Wenqi.
560 cases of adverse drug reaction/event caused by Mailu Shutong pills
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 921-924.
|
[4] |
CHAO Ying, ZHANG Xuemei, ZHANG Chengjian, WANG Bei.
One case of ureterolith combined with gallstone caused by Ceftriaxone sodium for injection in children
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 943-945.
|
[5] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[6] |
CHENG Yijing, LI Tao, LIU Junting, HUANG Guimin, ZHONG Xuli, LIN Aihua, PAN Shoudong, LI Long, BAI Dongsheng, ZHAN Xiaojun, LIU Zhenjiang, REN Wei, NIE Xiaolu, TAI Jun.
Safety evaluation of haemocoagulase agkistrodon for injection in children based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 787-790.
|
[7] |
LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu.
Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
|
[8] |
NIE Xiaolu, MA Jingyao, SUN Feng, ZHAN Siyan.
Pathogenesis and diagnosis of drug-induced thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 829-835.
|
[9] |
HJELMSTRÖM Peter, BOWRING Geoffrey, YUE Qun-Ying, NORÉN G. Niklas.
Methods for signal management using the global safety database VigiBase
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 836-840.
|
[10] |
YU Jing, PALATI Reheman, ZHAO Ting, FENG Jirong, SUN Yan, HE Lei.
Correlation of the efficacy, safety and plasma concentration of lacosamide in the treatment of children with epilepsy under 4 years of age
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 559-562.
|
[11] |
LIU Jie, ZHANG Jianmin, ZHANG Xiaomeng, LIU Fang, SONG Yuan, ZHONG Xuli.
Management of risks to pediatric medications based on drug instructions of Chinese patent medicines in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 422-427.
|
[12] |
YANG Bo, WANG Mengjiao, HU Lili, WANG Laicheng, LI Qian, KONG Feifei, LYU Dongmei, SHEN Jiani.
Safety assessment and risk factor analysis of PD-1 immunotherapy in a cohort of 385 patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 447-450.
|
[13] |
LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong.
Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
|
[14] |
LI Shaoqiang, KONG Xudong, LI Pengmei.
One case of hyponatremia caused by omeprazole sodium for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 461-463.
|
[15] |
WU Shiqi, YAN Suying, ZHANG Qingxia.
Research progress in pharmacokinetic interactions of edoxaban
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 473-480.
|